Bristol Myers reports Q4 adjusted EPS $1.26, consensus $1.20

Reports Q4 revenue $12.5B, consensus $12.28B. “We made significant progress in 2025, with real momentum in our Growth Portfolio and a strengthened balance sheet that provides the strategic flexibility to continue investing in growth drivers,” said Christopher Boerner, Ph.D., board chair and CEO, Bristol Myers (BMY) Squibb. “2026 is data-rich, and we are advancing a truly differentiated pipeline with multiple pivotal readouts expected in the back half of the year. Our core business is strong and growing, and we have the potential to achieve industry-leading, sustainable growth into the 2030s and beyond.”